Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

Trial ID or NCT#

NCT04476472

Status

not recruiting iconNOT RECRUITING

Purpose

Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting, and an optional 12-month extension phase.

Official Title

Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children With Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort

Eligibility Criteria

Ages Eligible for Study: 2 Years to 5 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Age at time of consent 2.0-5.9 years2. Living with parent/legal guardian3. Diagnosed with type 1 diabetes. Diagnosis is based on investigator's clinical judgment4. Deemed appropriate for pump therapy per investigator's assessment taking into account previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities5. Investigator has confidence that the subject and/or parent/guardian/caregiver can successfully operate all study devices and is capable of adhering to the protocol6. Willing to use only the following types of insulin during the study: Humalog, Novolog, Admelog or Apidra during the study7. Willing to wear the system continuously throughout the study8. Willing to participate in challenges for 2 consecutive days, consisting of a minimum of 3 hours of activity per day and dietary challenge by reducing the number of carbohydrates entered for a given meal by 50%9. A1C \<10% at screening visit10. Subject and/or parent/guardian must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as the sole source of Dexcom data (with the exception of the Dexcom Follow App) during the hybrid closed-loop phase11. Subject and/or parent/guardian is able to read and speak English fluently12. Has a parent/legal guardian willing and able to sign the ICF.
Exclusion Criteria:
  1. 1. A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk2. History of severe hypoglycemia in the past 6 months3. History of DKA in the past 6 months, unrelated to an intercurrent illness, infusion set failure or initial diagnosis4. Diagnosed with sickle cell disease5. Diagnosed with hemophilia or any other bleeding disorders6. Plans to receive blood transfusion over the course of the study7. Clinical evidence of acute or chronic kidney disease (e.g. estimated GFR \< 45) or currently on hemodialysis8. History of adrenal insufficiency9. Has taken oral or injectable steroids within the past 8-weeks or plans to take oral or injectable steroids during the course of the study10. Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement11. Plans to use insulin other than U-100 insulin intended for use in the study device during the course of the study12. Use of non-insulin anti-diabetic medication other than metformin (e.g. GLP1 agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide)13. Thyroid Stimulating Hormone (TSH) is outside of normal range with clinical signs of hypothyroidism or hyperthyroidism14. Currently participating or plans to participate in another clinical study using an investigational drug or device other than the Omnipod Horizon™ Automated Glucose Control System during this study period15. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
View All Criteria
Show Less

Investigator(s)

Bruce Buckingham
Bruce Buckingham
Endocrinologist
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus

Contact us to find out if this trial is right for you.

Contact

Ryan Kingman

View on ClinicalTrials.gov